Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Mallinckrodt agrees to $1.6 bln opioid settlement, unit to seek bankruptcy

Stock MarketsFeb 25, 2020 03:49PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. Bottles of prescription painkillers Hydrocodine Bitartrate and Acetaminopohen, 5mg/325mg pills, made by Mallinckrodt sit on a shelf at a local pharmacy

By Saumya Joseph and Nate Raymond

(Reuters) - Mallinckrodt (NYSE:MNK) Plc on Tuesday said it had agreed to a $1.6 billion settlement proposal in which its generic drug business would file bankruptcy in order to resolve thousands of lawsuits alleging it helped fuel the U.S. opioid epidemic.

The settlement was reached with a key committee that represents thousands of local governments pursuing lawsuits against opioid companies and was supported by a group of 47 state and U.S. territory attorneys general, the company said.

Mallinckrodt is the third opioid maker to consider bankruptcy protection as it deals with mounting expenses tied to lawsuits by thousands of U.S. states and local governments, holding them accountable for the U.S. opioid epidemic.

California Attorney General Xavier Becerra in a statement called Mallinckrodt's proposed settlement "a step in the right direction."

Around 3,000 lawsuits have been filed accusing drug manufacturers of engaging in deceptive marketing that promoted the use of addictive painkillers and fueled the epidemic that since 1999 has resulted in more than 400,000 overdose deaths.

Other opioid companies who have filed for bankruptcy include Insys Therapeutics Inc and the OxyContin maker Purdue Pharma LP, which sought bankruptcy protection in September after reaching a tentative deal it values at $10 billion to resolve the cases against it.

Paul Hanly, a lead attorney for the local governments, welcomed Mallinckrodt's settlement proposal, saying he was "hopeful that support for the deal will be widespread."

Seven states have not signed onto Mallinckrodt's proposal, including New York, which is set to take several opioid companies to trial on March 20.

New Hampshire Associate Attorney General James Boffetti said his state was holding off from signing on, saying the proposal "lacks specificity" as to how the money would be distributed.

Settlement talks are ongoing with other companies. Twenty-one states recently rejected an $18 billion settlement proposal from three major U.S. drug distributors, though discussions remain active, sources told Reuters this month. [nNRAaz3b12]

Mallinckrodt said it would retain ownership of the speciality generics business after the completion of the bankruptcy process and would continue to evaluate strategic options for the unit.

Since last year, Mallinckrodt has been working to separate the business and had said it was considering several options.

The company also said it had entered into an agreement with some of its existing lenders under which it could receive a new $800 million four-year term loan.

Shares of Mallinckrodt were trading in the afternoon at $4.77, up 16.9%.

Mallinckrodt agrees to $1.6 bln opioid settlement, unit to seek bankruptcy

Related Articles

Cognac sales jump 31% as drinkers go upmarket
Cognac sales jump 31% as drinkers go upmarket By Reuters - Jan 17, 2022 2

PARIS (Reuters) - Cognac sales surged by a nearly a third last year as American and Chinese drinkers guzzled old vintages, in the latest sign premium drinks makers are putting the...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email